These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10460693)

  • 21. The role of endothelins and their receptors in heart failure.
    Giannessi D; Del Ry S; Vitale RL
    Pharmacol Res; 2001 Feb; 43(2):111-26. PubMed ID: 11243712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics.
    Dupuis J
    Can J Cardiol; 2000 Jul; 16(7):903-10. PubMed ID: 10934309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelin antagonists.
    Benigni A; Remuzzi G
    Lancet; 1999 Jan; 353(9147):133-8. PubMed ID: 10023915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role of endothelins in human cardiovascular disease].
    Negrusz-Kawecka M
    Pol Merkur Lekarski; 2001 Nov; 11(65):444-6. PubMed ID: 11852820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelin System in Hypertension and Chronic Kidney Disease.
    Schiffrin EL; Pollock DM
    Hypertension; 2024 Apr; 81(4):691-701. PubMed ID: 38059359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Endothelins: possibly a new pharmacological approach in cardiovascular diseases, kidney diseases and oncological disorders].
    Kroodsma JM; Rabelink AJ
    Ned Tijdschr Geneeskd; 1997 Sep; 141(38):1806-10. PubMed ID: 9545734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basic and therapeutic relevance of endothelin-mediated regulation.
    Goto K
    Biol Pharm Bull; 2001 Nov; 24(11):1219-30. PubMed ID: 11725953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic oral endothelin type A receptor antagonism in experimental heart failure.
    Borgeson DD; Grantham JA; Williamson EE; Luchner A; Redfield MM; Opgenorth TJ; Burnett JC
    Hypertension; 1998 Mar; 31(3):766-70. PubMed ID: 9495259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin and endothelin receptor antagonism in heart failure.
    Sütsch G; Kiowski W
    J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S69-73. PubMed ID: 10976786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The endothelin-aldosterone axis and cardiovascular diseases.
    Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelin in atherosclerosis: importance of risk factors and therapeutic implications.
    d'Uscio LV; Barton M; Shaw S; Lüscher TF
    J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S55-59. PubMed ID: 10976783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelin.
    Kawanabe Y; Nauli SM
    Cell Mol Life Sci; 2011 Jan; 68(2):195-203. PubMed ID: 20848158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelin in cardiovascular control: the role of endothelin antagonists.
    Wenzel RR; Czyborra P; Lüscher T; Philipp T
    Curr Hypertens Rep; 1999; 1(1):79-87. PubMed ID: 10981046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic implications of endothelin antagonists for cardiovascular diseases].
    Abassi Z; Ramadan R; Schwartz H; Hoffman A
    Harefuah; 2004 Jan; 143(1):47-53, 84. PubMed ID: 14748289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Endothelin-1 and cardiovascular diseases].
    Cracowski JL; Stanke F; Bessard G
    Rev Med Interne; 1999 Jul; 20(7):589-96. PubMed ID: 10434349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
    Holm P
    Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelin ETA receptor antagonism in cardiovascular disease.
    Nasser SA; El-Mas MM
    Eur J Pharmacol; 2014 Aug; 737():210-3. PubMed ID: 24952955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition.
    Kaoukis A; Deftereos S; Raisakis K; Giannopoulos G; Bouras G; Panagopoulou V; Papoutsidakis N; Cleman MW; Stefanadis C
    Curr Top Med Chem; 2013; 13(2):95-114. PubMed ID: 23470073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure.
    Mulder P; Richard V; Bouchart F; Derumeaux G; Münter K; Thuillez C
    Cardiovasc Res; 1998 Sep; 39(3):600-8. PubMed ID: 9861302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.
    Francis B; Winaver J; Karram T; Hoffman A; Abassi Z
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S54-8. PubMed ID: 15838359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.